Sysmex (OTCMKTS:SSMXY - Get Free Report) will likely be issuing its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of $0.0372 per share and revenue of $862.45 million for the quarter.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $837.32 million for the quarter, compared to analysts' expectations of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Sysmex Stock Up 0.2%
Shares of SSMXY opened at $8.42 on Wednesday. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of 17.54 and a beta of 1.10. Sysmex has a 1 year low of $8.15 and a 1 year high of $19.39. The business's 50 day simple moving average is $8.82 and its 200-day simple moving average is $9.57. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44.
Analysts Set New Price Targets
Separately, Citigroup cut Sysmex from a "strong-buy" rating to a "hold" rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold".
Read Our Latest Stock Analysis on SSMXY
About Sysmex
(
Get Free Report)
Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
